J&J-Merck Pepcid AC is number one OTC acid relief product with 24% share.
This article was originally published in The Tan Sheet
Executive Summary
J&J-MERCK PEPCID AC IS NUMBER ONE OTC ACID RELIEF PRODUCT with a market share of about 22% at the end of November, Merck Senior VP Judy Lewent told a meeting of securities analysts at the company's Whitehouse Station, N.J. headquarters Dec. 12. The OTC version of the H2 antagonist famotidine, launched in June, is "the number one product in the acid relief category, surpassing older antacid products and thus far successfully thwarting the challenge by [SmithKline Beecham's] Tagamet HB," Lewent declared.